Tag Archives: Advisory Commitee

  1. Sarepta Advisory Committee Meeting

    Posted on April 22, 201611:45 pm

      As I prepare to travel to Monday’s Advisory Committee meeting I continue to be disappointed by the FDA Peripheral and Central Nervous System Drugs Advisory Committee’s initial review of Sarepta’s Duchenne muscular dystrophy drug eteplirsen. Despite this news we need to remember The FDA’s initial reaction is just that – an initial response – Read more »

  2. CUREDUCHENNE RESPONDS TO FDA ADVISORY COMMITTEE MEETING ON DRISAPERSEN FOR DUCHENNE MUSCULAR DYSTROPHY

    Posted on November 25, 201512:05 am

    CureDuchenne, the California-based nonprofit organization dedicated to finding cures for Duchenne muscular dystrophy, released the following statement from its co-founder and CEO, Debra Miller, following the meeting of the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA). The FDA will consider the committee’s discussions, and has set a Read more »

  3. BioMarin Quarterly Update to the Duchenne Community

    Posted on November 20, 201512:47 am

      CureDuchenne is pleased to share the BioMarin Quarterly Update to the Duchenne Community.   It covers important information about next week’s FDA Advisory Committee meeting and other key updates from the company.     November 2015 BioMarin: Quarterly Update to the Duchenne Community Welcome to the second of the BioMarin quarterly updates. As you can Read more »